Association between plasma 25-hydroxyvitamin D and breast cancer risk

Cancer Prevention Research

Volumn 2, Issue 6, 2009, Pages 598-604

  Crew, Katherine D ^a,b   Gammon, Marilie D ^d   Steck, Susan E ^e   Hershman, Dawn L ^a,b   Cremers, Serge ^a   Dworakowski, Elzbieta ^a   Shane, Elizabeth ^a   Terry, Mary Beth ^a,b   Desai, Manisha ^a,b   Teitelbaum, Susan L ^c   Neugut, Alfred I ^a,b   Santella, Regina M ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b Herbert IrvingComprehensive Cancer Center ^*  (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d IL   (United States)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; HORMONE RECEPTOR; VITAMIN D; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK REDUCTION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; BLOOD; BODY MASS; BREAST TUMOR; CARCINOMA IN SITU; CASE CONTROL STUDY; CHEMISTRY; ETHNIC GROUP; MIDDLE AGED; NEOPLASM; PAGET NIPPLE DISEASE; RISK; SEASON; UNITED STATES;

AGED; BODY MASS INDEX; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; CASE-CONTROL STUDIES; ESTROGENS; ETHNIC GROUPS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NEW YORK; POSTMENOPAUSE; PROGESTERONE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK; SEASONS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 68949187845     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0138     Document Type: Article

References (41)

1. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 α-hydroxylase. J Clin Endocrinol Metab 2001;86:888-894
2. Colston KW, Hansen CM. Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002;9:45-59.
3. Gorham ED, Garland FC, Garland CF. Sunlight and breast cancer incidence in the USSR. Int J Epidemiol 1990;19:820-824
4. Garland FC, Garland CF, Gorham ED, Young JF. Geographic variation in breast cancer mortality in the United States: a hypothesis involvingexposure to solar radiation. Prev Med 1990;19:614-622
5. Grant WB. An ecologic study of dietary and solar ultraviolet-B links to breast carcinoma mortality rates. Cancer 2002;94:272-281
6. Welsh J. Vitamin D and breast cancer: insights from animal models. Am J Clin Nutr 2004;80:1721-4S.
7. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controllingbr east cancer cell proliferation. Lancet 1989;1:188-191 (Pubitemid 19038805)
8. Saez S, Falette N, Guillot C, et al. William L. McGuire Memorial Symposium. 1,25(OH)2D3 modulation of mammary tumor cell growth in vitro and in vivo. Breast Cancer Res Treat 1993;27:69-81.
9. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE. 1 α,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res 2000;87:214-220
10. Cui Y, Rohan TE. Vitamin D, calcium, and breast cancer risk: a review. Cancer Epidemiol Biomarkers Prev 2006;15:1427-1437
11. Iqbal SJ. Vitamin D metabolism and the clinical aspects of measuringmet abolites. Ann Clin Biochem 1994;31:109-124
12. Hollis BW. Assessment of vitamin D nutritional and hormonal status: what to measure and how to do it. Calcif Tissue Int 1996;58:4-5.
13. Gammon MD, Neugut AI, Santella RM, et al. The Long Island Breast Cancer Study Project: description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res Treat 2002;74:235-254
14. Roth HJ, Schmidt-Gayk H, Weber H, Niederau C. Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann Clin Biochem 2008;45:153-159
15. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int 2005;16:713-716
16. Yetley EA. Assessing the vitamin D status of the US population. Am J Clin Nutr 2008;88:558-64S.
17. Hosmer DW, Lemeshow S. Applied Logistic Regressioned. New York (NY): John Wiley & Sons; 1989.
18. Newmark HL, Heaney RP, Lachance PA. Should calcium and vitamin D be added to the current enrichment program for cereal-grain products? Am J Clin Nutr 2004;80:264-270
19. Lowe LC, Guy M, Mansi JL, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 2005;41:1164-1169
20. Janowsky EC, Lester GE, Weinberg CR, et al. Association between low levels of 1,25-dihydroxyvitamin D and breast cancer risk. Public Health Nutr 1999;2:283-291
21. Abbas S, Linseisen J, Slanger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large case-control study. Carcinogenesis 2008;29:93-99
22. Bertone-Johnson ER, Chen WY, Holick MF, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1991-1997.
23. Freedman DM, ChangSC, Falk RT, et al. Serum levels of vitamin d metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screeningtri al. Cancer Epidemiol Biomarkers Prev 2008;17:889-894
24. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007;85:1586-1591
25. Zhou W, Heist RS, Liu G, et al. Circulating25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lungcancer patients. J Clin Oncol 2007;25:479-485
26. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502-1508 (Pubitemid 39202318)
27. Vieth R, Cole DE, Hawker GA, TrangHM, Rubin LA. Wintertime vitamin D insufficiency is common in youngCanadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 2001;55:1091-1097
28. Shin MH, Holmes MD, Hankinson SE, et al. Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst 2002;94:1301-1311
29. Lin J, Manson JE, Lee IM, et al. Intakes of calcium and vitamin D and breast cancer risk in women. Arch Intern Med 2007;167:1050-1059 (Pubitemid 46835793)
30. Robien K, Cutler GJ, Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. Cancer Causes Control 2007;18:775-782
31. McCullough ML, Rodriguez C, Diver WR, et al. Dairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2898-2904
32. Kailajarvi ME, Salminen EK, Paija OM, et al. Serum bone markers in breast cancer patients during 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy. Anticancer Res 2004;24:1271-1274
33. Gao Y, Shimizu M, Yamada S, Ozaki Y, Aso T. The effects of chemotherapy includingci splatin on vitamin D metabolism. Endocr J 1993;40:737-742 (Pubitemid 24085041)
34. Crew KD, Shane E, Cremers S, et al. High prevalence of vitamin D deficiency in a multi-ethnic cohort of premenopausal breast cancer patients. Proceedings of the American Society of Clinical Oncology 2008.
35. Jacobson EA, James KA, Newmark HL, Carroll KK. Effects of dietary fat, calcium, and vitamin D on growth and mammary tumorigenesis induced by 7,12-dimethylbenz(a)anthracene in female Sprague-Dawley rats. Cancer Res 1989;49:6300-6303
36. Abbas S, Linseisen J, Chang-Claude J. Dietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study. Nutr Cancer 2007;59:54-61.
37. Chlebowski RT, Johnson KC, KooperbergC, et al. The Women's Health Initiative randomized trial of calcium plus vitamin D: effects on breast cancer and arthralgias. Proceedings of the American Society of Clinical Oncology 2006.
38. National Academy of Sciences, Institute of Medicine, Food and Nutrition Board, Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluorideed. Washington (DC): National Academy Press; 1997. p. 7-30.
39. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosingwith cholecalciferol. Am J Clin Nutr 2003;77:204-210
40. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. Am J Clin Nutr 2007;85:6-18.
41. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007;103:708-711